A Phase 3 Study (TILVANCE-301) to Assess the Efficacy and Safety of Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Combination with Pembrolizumab Compared with Pembrolizumab Alone in Patients with Untreated Unresectable or Metastatic Melanoma.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
Intratumor Heterogeneity,Tumor Regression,T Cell Therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要